Business
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated:“2025 was a year of profound transformation for Novo Nordisk and this extraordinary period has taught us some important lessons. We are reshaping our traditional approach to patient care and market access, and we need to meet patients where they are. The year ahead will test our determination and capabilities, and
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"text","content":"Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting.","length":96,"tagName":"p"},{"type":"text","content":"At the Annual General Meeting, Lars Rebien Sørensen, chair of the Board of Directors, stated:“2025 was a year of profound transformation for Novo Nordisk and this extraordinary period has taught us some important lessons. We are reshaping our traditional approach to patient care and market access, and we need to meet patients where they are. The year ahead will test our determination and capabilities, and we face it with confidence, knowing that our renewed focus, strengthened competencies and uncompromising commitment to people with serious chronic diseases position us well for the challenges and opportunities ahead.”","length":627,"tagName":"p"},{"type":"text","content":"Resolutions adopted at the Annual General MeetingFinancial year 2025 and remuneration","length":86,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Approval of the Company’s statutory Annual Report 2025 and distribution of profits according to the statutory Annual Report 2025.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"The final dividend for 2025 of DKK 7.95 for each Novo Nordisk A and B share of DKK 0.10. The total dividend for 2025 of DKK 11.70 includes both the interim dividend of DKK 3.75 for each Novo Nordisk A and B share of DKK 0.10, which was paid in August 2025, and the final dividend of DKK 7.95 for each Novo Nordisk A and B share of DKK 0.10 to be paid in March 2026.","length":365,"tagName":"p"}]},{"val":[{"type":"text","content":"Approval of the Remuneration Report 2025 (advisory vote) and of the remuneration of the Board of Directors for 2026.","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":610,"olType":false},{"type":"t...